Clinical trials: Upper Limb
Covid19
Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)
This is an open-label unblinded, randomized study to treat hospitalized covid-19 patients with colchicine plus current care (per institution treating physicians) vs.
- Trial name
- Colheart-19 (NCT04762771)
- Testing
- Colchicine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Baptist Health South Florida
Lymphoma, Non Hodgkin
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
This open-label, single-arm, phase IIIb study will evaluate the safety of switching from intravenous (IV) to subcutaneous (SC) administration of rituximab during first-line treatment for participants with CD20+ non-Hodgkin's…
- Trial name
- NCT01987505
- Testing
- Rituximab
- Where
- 39 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Cancer
Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90
- Trial name
- NCT01848756
- Testing
- SNX-5422
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Esanex Inc.
Prostate Cancer
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this phase 2, open-label, single-arm, multidose, multicenter study is to investigate the effects of Orteronel plus Prednisone on the QT/QTc interval in patients with Metastatic Castration-Resistant Prostrate Cancer
- Trial name
- NCT01549951
- Testing
- Orteronel+Prednisone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Smoking Cessation
A First-in-Human Study of SBP-9330 in Healthy Subjects
This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.
- Trial name
- NCT04948827
- Testing
- SBP-9330
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Camino Pharma, LLC
Pneumococcal Disease
A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.
The purpose of this study is to learn about the safety and immune response of 20vPnC in adults in India. This study is seeking participants who: are generally healthy adults of 18 years or older.
- Trial name
- NCT05875727
- Testing
- 20-valent pneumococcal conjugate vaccine
- Where
- 8 sites in India
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Study of Remdesivir in Participants Below 18 Years Old With COVID-19
The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).
- Trial name
- CARAVAN (NCT04431453)
- Testing
- Remdesivir
- Where
- 32 sites in United States, Italy and 2 more
- Volunteers
- 59 people
- Sponsor
- Gilead Sciences
Stroke
Evaluation of Robotic Arm Rehabilitation in Stroke Patients
The purpose of this study is to compare 2 training programs using robotic exercise devices to supervised arm exercises in stroke patients with chronic stable deficits.
- Trial name
- NCT00333983
- Testing
- Robotic Upper Extremity Neurorehabilitation, Traditional Upper Extremity Exercise Group
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- US Department of Veterans Affairs
End Stage Renal Disease
Monitoring in Dialysis -- a Prospective, Multi-center, Single-arm, Non-randomized, Observational Study in Patients Who Are Undergoing Hemodialysis.
The primary objective of this study is to estimate the proportion of hemodialysis patients experiencing clinically significant cardiac arrhythmias over a 6-month period using continuous cardiac monitoring with an implanted…
- Trial name
- MiD (NCT01779856)
- Testing
- REVEAL Insertable Cardiac Monitor (ICM)
- Where
- 10 sites in United States, India
- Volunteers
- 81 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be evaluated on the basis of response rate, when administered to patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)
- Conditions
- Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
- Trial name
- NCT00233454
- Testing
- Midostaurin
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Jason Robert Gotlib
Stroke, Cerebrovascular Accident (CVA)
The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
The purpose of this study is to evaluate if 5 consecutive sessions of PathMaker anodal DoubleStim treatment, which combines non-invasive stimulation of the spinal cord (tsDCS- trans-spinal direct current stimulation) and of the…
- Conditions
- Stroke, Cerebrovascular Accident (CVA), Hemiparesis, Spasticity as Sequela of Stroke
- Trial name
- NCT03080454
- Testing
- anodal Doublestim
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northwell Health
Postoperative Pain
Maxigesic® IV Phase 3 Exposure Study
The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.
- Trial name
- NCT04005755
- Testing
- Maxigesic® IV
- Where
- 4 sites in United States, New Zealand
- Volunteers
- 232 people
- Sponsor
- AFT Pharmaceuticals, Ltd.
Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects of pembrolizumab and vorinostat in treating patients with squamous cell head and neck cancer or salivary gland cancer that has come back, has spread to other places in the body…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Salivary Gland Carcinoma
- Trial name
- NCT02538510
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Coronary Artery Disease
Shockwave Coronary Lithoplasty® Study (Disrupt CAD II)
The objective of this post market study is to examine the safety and performance of the Shockwave Coronary Intravascular Lithotripsy System for the treatment of narrowed coronary arteries before the doctor places a stent.
- Trial name
- NCT03328949
- Testing
- IVL Coronary Lithotripsy System
- Where
- 15 sites in Belgium, Denmark and 7 more
- Volunteers
- 120 people
- Sponsor
- Shockwave Medical, Inc.
HIV
Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
This is a Phase 2b/3, multi-center, two part study, designed to evaluate the efficacy, safety, and tolerability of PRO 140 in conjunction with existing ART (failing regimen) for one week and Optimized Background Therapy (OBT) for…
- Trial name
- PRO140 (NCT02483078)
- Testing
- PRO 140, Optimized Background Regimen
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 52 people
- Sponsor
- CytoDyn, Inc.
Infections After Lung Transplant
Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement
Immunosuppressive therapies have led to remarkable improvements in survival in lung transplantation (LT) patients. However, one important adverse effect of these therapies has been the increasing emergence of…
- Trial name
- NCT01361178
- Testing
- SQ IVIG
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- University of Pittsburgh
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
Primary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on response when metastatic breast cancer patients are treated with DNA damaging chemotherapy agent, compared to historical controls…
- Trial name
- NCT01990352
- Testing
- Pegylated liposomal doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Arizona
Multiple Sclerosis, Relapsing-Remitting
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active…
- Trial name
- NCT00050778
- Testing
- Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg
- Where
- 49 sites in United States, Croatia and 3 more
- Volunteers
- 334 people
- Sponsor
- Genzyme, a Sanofi Company
Plasmodium Falciparum Malaria
Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
The purpose of this study was to evaluate PK, safety, tolerability and efficacy of a new formulation of artemether-lumefantrine dispersible tablet in neonates and infants <5 kg body weight with acute uncomplicated Plasmodium…
- Trial name
- CALINA (NCT04300309)
- Testing
- artemether:lumefantrine (2.5 mg:30 mg)
- Where
- 3 sites in Burkina Faso, Democratic Republic of the Congo
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.